Type A meeting with U.S. FDA scheduled to discuss Deramiocel BLA and path toward potential approvalCapricor seeks to resubmit ...

Despite zero revenue and increased losses, Capricor Therapeutics Inc (CAPR) focuses on strategic initiatives and regulatory ...

Capricor Therapeutics, Inc. (CAPR) is scheduled to announce Q2 earnings results on Wednesday, August 13th, after market close. The consensus EPS Estimate is -$0 ...

Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.

NEW YORK - August 12, 2025 ( NEWMEDIAWIRE) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases.

Capricor Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights - CAPR ...

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPRLOS ANGELES-- (BUSINESS WIRE)--Centene Corporation Investigated for ...

About Capricor Therapeutics Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment ...

Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.

Capricor Therapeutics Inc.‘s board overhyped regulatory approval odds for its cell therapy to treat a serious heart condition, leading to a series of stock drops, a shareholder lawsuit said.

The law firm of Kirby McInerney LLP reminds investors who purchased Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR) securities to contact Thomas W. Elrod of Kirby McInerney LLP ...